(Q42614732)

English

Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic

scientific article published on November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1 reference

based on heuristic

inferred from title

expanded access

1 reference

based on heuristic

inferred from title

author name string

N Kontorinis

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

G Garas

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

J Young

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

D Speers

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

B P Chester

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

G C MacQuillan

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

B De Boer

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

M D Chapman

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

E Forster

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

G P Jeffrey

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Internal Medicine Journal

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

500-504

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Epidemiology of hepatitis C: geographic differences and temporal trends

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Adverse effects and other safety aspects of the hepatitis C antivirals

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2003.00410.X

21 January 2018

Identifiers

10.1046/J.1445-5994.2003.00410.X

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42614732&oldid=1962857954"